The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. - Wikidata - awgldk - TriplyDB

The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.

The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.

http://www.wikidata.org/entity/Q43700541

about

Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma Integrin engagement regulates monocyte differentiation through the forkhead transcription factor Foxp1 Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma Drug inhibition profile prediction for NFκB pathway in multiple myeloma Lenalidomide for the treatment of relapsed and refractory multiple myeloma.Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells.Regulation of HIV-1 transcription in cells of the monocyte-macrophage lineage.Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function.Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells.TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells Molecular sequelae of proteasome inhibition in human multiple myeloma cells MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells.Novel therapeutic approaches for multiple myeloma.Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.Pathogenesis beyond the cancer clone(s) in multiple myeloma.Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications Molecular biological design of novel antineoplastic therapies.ADAM-9 (MDC-9/meltrin-gamma), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the alpha(v)beta5 integrin.Targeting signalling pathways for the treatment of multiple myeloma.Bone marrow microenvironment and the identification of new targets for myeloma therapy.Therapeutic renaissance of thalidomide in the treatment of haematological malignancies.Proteasome inhibition as a therapeutic strategy for hematologic malignancies.Growth factors and antiapoptotic signaling pathways in multiple myeloma.A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, β-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice.Current therapeutic uses of lenalidomide in multiple myeloma.Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities Surface-tension driven open microfluidic platform for hanging droplet culture.Proteasome inhibitor bortezomib for the treatment of multiple myeloma.Blocking the ZZ domain of sequestosome1/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo.The role of microenvironment in tumor angiogenesis.Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.

P2860

Q21285161-5123C96C-189E-4585-8AC8-F9EC657D8537 Q24300381-F82DECCD-9041-4356-BF4C-BE677A791DBC Q24570128-2A7BDCA6-B7C9-49DB-ABF3-0ACFEE1041C1 Q24605861-A815CFBB-37CF-45EC-9FF1-FCF29B6B99F7 Q24669763-00832BF5-BB2C-4648-925A-CCDF7E991A57 Q24670297-744C6AA4-8012-4C19-9547-6B9485742876 Q28271286-EAEC57A2-3CAE-48F1-B0DA-FB9CEF5D3934 Q28477374-F63ABE13-085D-40EE-BEA0-5CDED20256E9 Q33403183-D2B08368-B3A6-47F3-9DFB-87D0C50C6785 Q33413142-1C356DE0-D494-45C4-9F1D-91DF501D0D29 Q33577408-72434AE7-A071-4F19-A6EF-8F6752E4F12E Q33584749-4A785F80-FD9D-4289-BEC5-2FEA1B36067B Q33587139-F3D85C46-5EE4-4318-936D-F84D0C6F6103 Q33854012-ADE77768-5840-4099-9AA2-CA4D9C295E09 Q34051633-622D29E9-C167-4C03-B50F-F8FC4199D651 Q34104277-8FD3CB06-B3FF-4C1B-8BE1-6F936D066E50 Q34134557-ECB18F6B-A762-4F46-98DB-F63B0C234E83 Q34393832-48385469-1C36-4DB1-81BE-67DE06D94B80 Q34914713-25C22E33-182E-473D-9527-0D6F0E641E1F Q35170935-D5149E06-3AD0-48FA-922F-1260975B422C Q35171777-78392629-836F-49E5-9823-EA9F1414BEF6 Q35552693-10742D74-EACF-4367-BF03-60F9E12DF04A Q35607266-D5277EAA-DD90-493C-BDC9-E1BCC4DE6A6F Q35616060-4C5DA50F-84EB-4C3C-BB6A-5D1CFE6D0438 Q35734509-B9EBBC44-4263-43A4-93A1-14DFB5E98ACE Q35790781-A48C042A-921D-45FC-91B4-D0A0BE9A4AE1 Q35849601-C4B383FE-FAC0-47FE-AC75-1A57D5A3E614 Q36150866-BD08D011-AF4F-458D-9CBF-8E3886B24B8A Q36162703-58AA03D9-18BA-4F99-9D78-74EE67D8D053 Q36171864-E6EC93F4-0B45-40D0-8B31-C8B0EEB0D2DB Q36185620-2BB778D7-BE1F-4768-AF98-545BEF83FB5D Q36292888-88B918EA-D8D7-4B13-9E4B-A32341E92E0C Q36356398-DF3F3CA4-0469-4675-9B0B-1D05097BA441 Q36376450-4A790A51-7183-42A2-AA00-949B2B2B0286 Q36447553-9A0FB409-41F4-4054-8734-9F25A4558538 Q36462782-875FD4E5-FC23-447F-8D2B-EA20DF88F401 Q36523911-DB2F7036-473D-44AA-9C7F-7A84D14CF711 Q36540462-B445B8B6-D399-4D49-A7BC-3FCC49CC1786 Q36558575-6E44FCF7-D792-454B-8903-B3C6DCE59F8D Q36589122-F3DD948F-BDFA-48CB-8B71-97CA7AE9482C

P2860

The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.

http://www.wikidata.org/entity/Q43700541

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

The role of tumor necrosis fac ...... oma: therapeutic applications.

@en

The role of tumor necrosis fac ...... oma: therapeutic applications.

@nl

type

label

The role of tumor necrosis fac ...... oma: therapeutic applications.

@en

The role of tumor necrosis fac ...... oma: therapeutic applications.

@nl

prefLabel

The role of tumor necrosis fac ...... oma: therapeutic applications.

@en

The role of tumor necrosis fac ...... oma: therapeutic applications.

@nl

P1433

Q43700541-2BDB0DA2-5B6F-4081-8486-41C82B78C5E5

P1476

Q43700541-14564DF2-7E40-47EE-B351-00187D5EADC1

P2093

Q43700541-354EA610-AB10-4DDA-ACA4-AE0717141E8E

Q43700541-39C6CBEF-463F-4158-9618-1D51CCFAB6B6

Q43700541-3C226D5E-D9B4-4B84-BA93-14300A3F23A1

Q43700541-9C960516-39E9-4EB6-B214-A80DA50A3742

Q43700541-E42DFA9F-C39F-4085-B4FC-52ED252C741D

P2860

Q43700541-29CF8C12-06CA-4999-AF70-4C9AD4B03297

Q43700541-2C884D19-B8F3-4379-B177-94B61B09B96E

Q43700541-30B49021-BEA5-4879-AD07-F31C4C84ABD8

Q43700541-5C779BE9-25FA-4433-8B8E-BEE3634A2790

Q43700541-AB443CC4-3978-48BC-B593-706662C5EABF

Q43700541-AEB161DB-BB20-4B7B-AD5E-FDE65681173D

Q43700541-B56514D5-AA5D-4BB8-9FCA-DEEDCABE4429

Q43700541-CB2261E1-D30F-475B-B3D6-9207D47D8D73

P2888

Q43700541-5A5AD31F-8AA3-4AFE-8ECC-D99EB5364795

P304

Q43700541-9D4C09E2-8205-4B23-9AB7-B6624E5EA5F5

P31

Q43700541-06467E12-68BE-455C-AA80-3D5B4B996354

P356

Q43700541-BDE72316-ABE5-4740-BCB6-ADE41741F1D9

P407

Q43700541-B6CE89A5-745B-4E5E-8D6D-672C71E20737

P433

Q43700541-22F7846F-E291-4F1D-9E2F-1731814162C9

P478

Q43700541-5EC0BEF8-1BD6-461B-A16E-ADA607499DD1

P577

Q43700541-7CC636DA-36FA-417F-941B-6743A653B497

P5875

Q43700541-75955FE5-6603-4C11-9C17-BE7183B84B7D

P6179

Q43700541-1D424783-C626-46CB-A3A0-B6A5D1C2A19E

P698

Q43700541-DD721495-2321-4E04-B5F5-C71247FE5459

P921

Q43700541-52FACD3B-7D21-4B59-A892-A3354F4DA021

P356

P1433

P1476

The role of tumor necrosis fac ...... oma: therapeutic applications.

@en

P2093

Anderson KC

http://www.w3.org/2001/XMLSchema#string

Chauhan D

http://www.w3.org/2001/XMLSchema#string

Hideshima T

http://www.w3.org/2001/XMLSchema#string

Richardson P

http://www.w3.org/2001/XMLSchema#string

Schlossman R

http://www.w3.org/2001/XMLSchema#string

P2860

Thalidomide is an inhibitor of angiogenesis

Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis

Antitumor activity of thalidomide in refractory multiple myeloma.

A multiple cytokine- and second messenger-responsive element in the enhancer of the human interleukin-6 gene: similarities with c-fos gene regulation.

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset.

Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells.

High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment.

P2888

P304

4519-4527

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.ONC.1204623

http://www.w3.org/2001/XMLSchema#string

P407

P433

33

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2001-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11850845

http://www.w3.org/2001/XMLSchema#string

P6179

1034738099

http://www.w3.org/2001/XMLSchema#string

P698

11494147

http://www.w3.org/2001/XMLSchema#string

P921

pathophysiology